Literature DB >> 10873086

Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer.

G Cox1, J L Jones, K J O'Byrne.   

Abstract

Matrix metalloproteinase (MMP)-9 is an endopeptidase that digests basement membrane type IV collagen. Enhanced expression has been related to tumor progression both in vitro and in vivo. The control of MMP transcription is complex, but recently, epidermal growth factor receptor (EGFR) expression has been implicated in up-regulation of MMP-9 in tumor cells in vitro. Our objective was to evaluate the relationship between MMP-9 and EGFR expression in non-small cell lung cancer (NSCLC) and to assess the impact of expression on clinicopathological parameters and survival. This is a retrospective study of 169 patients who underwent resection for stage I-IIIa NSCLC with a postoperative survival >60 days. Minimum follow-up was 2 years. Standard avidin-biotin complex immunohistochemistry was performed on 4-microm paraffin-embedded sections from the tumor periphery using monoclonal antibodies to EGFR and MMP-9. MMP-9 was expressed in the tumor cells of 88 of 169 (52%) cases. EGFR expression was found in 94 of 169 (56%) cases [membranous, 55 of 169 (33%); cytoplasmic, 39 of 169 (23%)]. MMP-9 expression was associated with poor outcome in univariate (P = 0.0023) and multivariate (P = 0.027) analysis. Membranous, cytoplasmic, and overall EGFR expression were not associated with outcome (P = 0.13, 0.99, and 0.17, respectively). MMP-9 expression showed a strong correlation with EGFR expression (P < 0.0001) and EGFR membranous expression (P = 0.002) but not with cytoplasmic EGFR expression (P = 0.18). Co-expression of MMP-9 and EGFR (37%) conferred a worse prognosis (P = 0.0001). Subset analysis revealed only MMP-9 and membranous EGFR co-expression (22%) was associated with poor outcome (P = 0.0019). Our results show that a significant proportion of NSCLC tumors co-express MMP-9 and EGFR. The co-expression of these markers confers a poor prognosis. This finding suggests that EGFR signaling pathway may play an important role in the invasive behavior of NSCLC via specific up-regulation of MMP-9.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873086

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  46 in total

1.  Effects of RNAi-mediated gene silencing of LRIG1 on proliferation and invasion of glioma cells.

Authors:  Feng Mao; Baofeng Wang; Guifa Xi; Wei Sun; Huaqiu Zhang; Fei Ye; Dongsheng Guo; Ting Lei
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-04-20

2.  MMP-9 polymorphisms are related to serum lipids levels but not associated with colorectal cancer susceptibility in Chinese population.

Authors:  Zhi-Hui Yang; Shi-Ning Li; Jin-Xing Liu; Qing-Xi Guo; Xing-Wang Sun
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

3.  Ubiquitin-conjugating enzyme E2C regulates apoptosis-dependent tumor progression of non-small cell lung cancer via ERK pathway.

Authors:  Zhongmian Zhang; Ping Liu; Jian Wang; Tianxiao Gong; Fang Zhang; Jun Ma; Na Han
Journal:  Med Oncol       Date:  2015-04-02       Impact factor: 3.064

4.  Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment.

Authors:  Heath B Acuff; Kathy J Carter; Barbara Fingleton; D Lee Gorden; Lynn M Matrisian
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

5.  Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer.

Authors:  Dongwei Zhang; Ana M Tari; Ugur Akar; Banu K Arun; Tiffany A LaFortune; Rene Nieves-Alicea; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Mol Cancer Ther       Date:  2010-11-02       Impact factor: 6.261

6.  A biological staging model for operable non-small cell lung cancer.

Authors:  G Cox; J L Jones; A Andi; D A Waller; K J O'Byrne
Journal:  Thorax       Date:  2001-07       Impact factor: 9.139

7.  Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer.

Authors:  Seok Jin Kim; Zahid N Rabbani; Fan Dong; Robin T Vollmer; Ernst-Gilbert Schreiber; Mark W Dewhirst; Zeljko Vujaskovic; Michael J Kelley
Journal:  Med Oncol       Date:  2009-02-24       Impact factor: 3.064

8.  Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.

Authors:  Joshua M Donaldson; Csaba Kari; Ruben C Fragoso; Ulrich Rodeck; John C Williams
Journal:  Cancer Biol Ther       Date:  2009-11-07       Impact factor: 4.742

Review 9.  A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells.

Authors:  Adam Yagui-Beltrán; David M Jablons
Journal:  Ann Thorac Cardiovasc Surg       Date:  2009-08       Impact factor: 1.520

10.  Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung.

Authors:  Ludmila Prudkin; Diane D Liu; Natalie C Ozburn; Menghong Sun; Carmen Behrens; Ximing Tang; Kathlynn C Brown; B Nebiyou Bekele; Cesar Moran; Ignacio I Wistuba
Journal:  Mod Pathol       Date:  2009-03-06       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.